SCHEMBL31729992

SCHEMBL31729992

O=c1cccc(-n2nnc3ccccc32)c(=O)[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.54
RAB9A P51151 1/20 0.43
POLB P06746 2/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HTT P42858 2/20 0.39
HPGD P15428 2/20 0.39
SLC9A1 P19634 2/20 0.39
APAF1 O14727 1/20 0.39
NPC1 O15118 1/20 0.39
TDP2 O95551 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
SMAD3 P84022 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25862494 0.74 KCNMA1 (0.64) KCNMA1RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL23840194 0.74 KCNMA1 (0.64) KCNMA1RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL8744193 0.74 KCNMA1 (0.64) KCNMA1RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL31730124 0.72 KDM4E (0.39) RAB9AKMT2AALDH1A1MEN1MAPT
SCHEMBL15537391 0.72 KCNMA1 (0.53) KCNMA1RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL30516128 0.72 KCNMA1 (0.53) KCNMA1RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL14421241 0.71 KCNMA1 (0.60) KCNMA1RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL30987402 0.71 KCNMA1 (0.60) KCNMA1RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL80393 0.70 KCNMA1 (1.00) KCNMA1RAB9APOLBSMN1; SMN2KMT2A
SCHEMBL16491892 0.70 KCNMA1 (0.64) KCNMA1RAB9APOLBSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2025-12-25 US disclosed
EP-4650348-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR Mitsubishi Tanabe Pharma Corporation (JP) 2025-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR CRBN, CUL1, CBL KCNMA1 2383/4885RAB9A 3850/4885POLB 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.